-
AstraZeneca presents conclusive results against neuromyelitis optica
19 Sep 2025 11:29 GMT
AstraZeneca has announced that Alexion, its … Ultomiris (ravulizumab), confirming sustained clinical benefit.
The data also indicate clinical …
-
Roivant, Pfizer's Therapy Shows ‘Patient-Centered Benefit’ in Rare Inflammatory Condition
18 Sep 2025 13:08 GMT
… , including Argenx’s subcutaneous efgartigimod, AstraZeneca’s anifrolumab and even Pfizer … steroid treatment.
Brepocitinib’s therapeutic benefits were evident as early as …
-
Pfizer Bets Big with $7.3 Billion Metsera Acquisition to Dominate Weight-Loss Market
23 Sep 2025 08:27 GMT
… M&A in obesity. AstraZeneca acquired Eccogene ($1.2B), and … -making and competition.
Patients may benefit as longer-acting, cheaper treatments …
-
DaltonTx raises £4 million seed financing to build the intelligence backbone of drug discovery
23 Sep 2025 08:52 GMT
… pioneering AI discovery platforms at AstraZeneca and Exscientia and bringing world … into real-world applications that benefit society. Find out more at …
-
In UK, Big Pharma pressure campaign rolls on as Bristol Myers plans US-level pricing for Cobenfy
23 Sep 2025 02:33 GMT
… are subject to cost/benefit scrutiny before medicines are made … for investment. Earlier this month, AstraZeneca paused a 200 million pound …
-
<![CDATA[Innovation in IgAN: Exploring New Therapies and Combination Approaches, With Brendon Neuen, MBBS, PhD]]>
22 Sep 2025 23:54 GMT
… reductions. Complement inhibitors also showed benefit with about a 35% reduction … over > 12 months indicating benefits for all drug classes, but … : Relevant disclosures for Neuen include AstraZeneca, Bayer, Boehringer and Ingelheim, Janssen …
-
Prurigo Nodularis market to exhibit growth at a CAGR of 23.2% (2020-2034), driven by strong uptake of DUPIXENT, recent approval of NEMLUVIO, promising JAK and OX40 inhibitors in the Pipeline, along with rising prevalence | DelveInsight
22 Sep 2025 22:58 GMT
… steroidal alternative with anti-inflammatory benefits. Moisturizers, or emollients, … , Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, … key bullous pemphigoid companies, including AstraZeneca, Kyowa Kirin, Regeneron, Sanofi …
-
Kidney failure risk higher for adults with diabetes, low eGFR
22 Sep 2025 20:00 GMT
… higher-risk patients may not benefit or [may] have unacceptable side … ; serving on speaker bureaus with AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Lilly … Therapeutics; consultant fees from Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly …
-
China Advances Services Trade
22 Sep 2025 20:16 GMT
… solutions and share in the benefits of China’s high-quality … industry-leading enterprises like Walmart, AstraZeneca and KPMG, offers a glimpse …
-
ILD remains leading cause of death in systemic sclerosis
22 Sep 2025 20:00 GMT
… can show the kind of benefit in SSc-ILD that they … are a lot of potential benefits here, including not needing long … :
Volkmann reports receiving grants from AstraZeneca, Atyr Pharma, Boehringer Ingelheim, GSK …
About
© 1995-2025